{Reference Type}: Journal Article
{Title}: Neonatal dysregulation of 2-arachidonoylglycerol induces impaired brain function in adult mice.
{Author}: Boo KJ;Kim DH;Cho E;Kim DH;Jeon SJ;Shin CY;
{Journal}: Neuropharmacology
{Volume}: 257
{Issue}: 0
{Year}: 2024 Oct 1
{Factor}: 5.273
{DOI}: 10.1016/j.neuropharm.2024.110045
{Abstract}: The endocannabinoid system (ECS) regulates neurotransmission linked to synaptic plasticity, cognition, and emotion. While it has been demonstrated that dysregulation of the ECS in adulthood is relevant not only to central nervous system (CNS) disorders such as autism spectrum disorder, cognitive dysfunction, and depression but also to brain function, there are few studies on how dysregulation of the ECS in the neonatal period affects the manifestation and pathophysiology of CNS disorders later in life. In this study, DO34, a diacylglycerol lipase alpha (DAGLα) inhibitor affecting endocannabinoid 2-AG production, was injected into C57BL/6N male mice from postnatal day (PND) 7 to PND 10, inducing dysregulation of the ECS in the neonatal period. Subsequently, we examined whether it affects neuronal function in adulthood through electrophysiological and behavioral evaluation. DO34-injected mice showed significantly decreased cognitive functions, attributed to impairment of hippocampal synaptic plasticity. The findings suggest that regulation of ECS activity in the neonatal period may induce enduring effects on adult brain function.